The stock’s meteoric rise was sparked by the news that the company’s experimental breast cancer vaccine NeuVax will continue in its two ongoing mid-stage studies as planned. The stock has settled to a 41.7% gain as of 11:35 a.m. EDT.
The stock’s meteoric rise was sparked by the news that the company’s experimental breast cancer vaccine NeuVax will continue in its two ongoing mid-stage studies as planned. The stock has settled to a 41.7% gain as of 11:35 a.m. EDT.